Department of Radiotherapy, A C Camargo Cancer Center, São Paulo, Brazil.
Radiat Oncol. 2018 Nov 20;13(1):224. doi: 10.1186/s13014-018-1168-x.
Patients with recurrent retroperitoneal and pelvic region tumors often require multimodal therapies. Intraoperative radiation therapy (IORT) can deliver high-dose radiation to tumor beds, even if first-line external beam radiation therapy (EBRT) was administered. We evaluated local control (LC) and survival in patients receiving IORT for recurrent tumors.
We retrospectively analyzed 41 patients with isolated pelvic or retroperitoneal recurrences of colorectal, gynecological, or retroperitoneal primary tumors. Following salvage surgery, all patients underwent tumor bed IORT via electron beam or high dose rate brachytherapy. Isolated IORT (median dose: 15 Gy) was administered to patients who had received first-line EBRT; other patients received IORT (median dose 12 Gy) plus EBRT. Local (LF), regional (RF), and distant failures (DF) were evaluated, and the Kaplan-Meier method and log-rank test were used to evaluate and compare overall survival (OS) from the date of IORT.
Forty-one patients underwent 44 treatments, including 27 (61.3%) isolated IORT and 17 (38.7%) IORT and EBRT combination regimens. The median follow-up was 8.1 years (range: 4.4-11.7 years), and the 2, 5, and 8 year overall LC rates were 87.9, 64.0, and 49.8%, respectively. Regarding resection status, the respective 2, 5, and 8 year LC rates were 90, 76, and 76% for R0 resection and 75, 25, and 0% for R1 resection (p < 0.001). The 2, 5, and 8 year OS rates were 68, 43, and 26%, respectively. OS was better among patients with LC (p < 0.001). Twenty-four patients (58.5%) experienced a DF, and the 5 year OS rates for the patients with and without DF were 36 and 52%, respectively (p = 0.04). In a multivariate analysis, LF (p = 0,012) and recurrent retroperitoneal sarcoma (p = 0,014) were identified as significant predictors of worse OS. Thirteen patients (31%) developed clinically treatable complications related to IORT.
Many patients achieve long-term OS and LC without significant morbidity after salvage surgery and IORT, especially in case of clear margins.
复发性腹膜后和盆腔区域肿瘤患者通常需要接受多模式治疗。术中放疗(IORT)可以向肿瘤床提供高剂量辐射,即使已经进行了一线外照射放疗(EBRT)。我们评估了接受 IORT 治疗复发性肿瘤的患者的局部控制(LC)和生存情况。
我们回顾性分析了 41 例孤立性盆腔或腹膜后结直肠、妇科或腹膜后原发性肿瘤复发的患者。在挽救性手术后,所有患者均通过电子束或高剂量率近距离放射疗法进行肿瘤床 IORT。接受过一线 EBRT 的患者接受单纯 IORT(中位剂量:15 Gy);其他患者接受 IORT(中位剂量 12 Gy)加 EBRT。评估局部(LF)、区域(RF)和远处失败(DF),并使用 Kaplan-Meier 方法和对数秩检验评估并比较从 IORT 日期开始的总生存期(OS)。
41 名患者接受了 44 次治疗,包括 27 次(61.3%)单纯 IORT 和 17 次(38.7%)IORT 和 EBRT 联合治疗。中位随访时间为 8.1 年(范围:4.4-11.7 年),2、5 和 8 年的总体 LC 率分别为 87.9%、64.0%和 49.8%。关于切除状态,RO 切除的相应 2、5 和 8 年 LC 率分别为 90%、76%和 76%,而 R1 切除的相应 2、5 和 8 年 LC 率分别为 75%、25%和 0%(p < 0.001)。2、5 和 8 年的 OS 率分别为 68%、43%和 26%。LC 患者的 OS 更好(p < 0.001)。24 名患者(58.5%)发生 DF,有和无 DF 的 5 年 OS 率分别为 36%和 52%(p = 0.04)。在多变量分析中,LF(p = 0.012)和复发性腹膜后肉瘤(p = 0.014)被确定为 OS 较差的显著预测因子。13 名患者(31%)出现与 IORT 相关的可临床治疗的并发症。
许多患者在挽救性手术和 IORT 后可长期无明显发病率并获得 LC,尤其是在切缘清晰的情况下。